Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Research
    • Research Library
    • Participate
      • Long-Term CBD Study
      • Observational Research Registry
      • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
      • Printable Resources
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Events
      • Book Club
      • Virtual Support Groups
    • Merch Shop
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Donate
    • Who We Are
    • In the News
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
    • Volunteer
  • Donate
  • Register
  • Login
  • Cannabinoid/s, excitotoxicity, experimental allergic encephalomyelitis, Multiple sclerosis (MS), neuroprotection
Loading...

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by in¯ammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice de®cient in the cannabinoid receptor CB1 tolerate in¯ammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide signi®cant neuroprotection from the consequences of in¯ammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes...
Read More

CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice

Abstract Traumatic brain injury (TBI) and its consequences represent one of the leading causes of death in young adults. This lesion mediates glial activation and the release of harmful molecules and causes brain edema, axonal injury, and functional impairment. Since glial activation plays a key role in the development of this damage, it seems that controlling it could be beneficial and could lead to neuroprotective effects. Recent studies show that minocycline suppresses microglial activation, reduces the lesion volume, and decreases TBI-induced locomotor hyperactivity up to 3 months. The endocannabinoid system (ECS) plays an important role in reparative mechanisms and inflammation under pathological situations by...
Read More

Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet

Paediatric traumatic brain injury (TBI) is a leading cause of death and disability. Previous studies showed neuroprotection after TBI by (endo)cannabinoid mechanisms, suggesting involvement of cannabinoid receptors (CBR). We therefore determined CBR densities and expression of the translocator protein 18 kDA (TSPO) in newborn piglets after experimental TBI. Newborn female piglets were subjected to sham operation (n=6) or fluid-percussion (FP) injury (n=7) under controlled physiological conditions. After six hours, brains were frozen, sagittally cut and incubated with radioligands for CBR ([3 HCP55,940, [3 H]SR141716A) and TSPO ([3 H]PK11195), an indicator of gliosis/brain injury. Early after injury, FP-TBI elicited a significant ICP increase at a...
Read More

Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia

Abstract Hypothermia is a standard treatment for neonatal encephalopathy, but nearly 50% of treated infants have adverse outcomes. Pharmacological therapies can act through complementary mechanisms with hypothermia improving neuroprotection. Cannabidiol could be a good candidate. Our aim was to test whether immediate treatment with cannabidiol and hypothermia act through complementary brain pathways in hypoxic-ischemic newborn piglets. Hypoxic-ischemic animals were randomly divided into four groups receiving 30 min after the insult: (1) normothermia and vehicle administration; (2) normothermia and cannabidiol administration; (3) hypothermia and vehicle administration; and (4) hypothermia and cannabidiol administration. Six hours after treatment, brains were processed to quantify the number of damaged...
Read More

Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage

Brain lesions induced in newborn mice or rats by the glutamatergic agonists ibotenate (acting on NMDA and metabotropic receptors) or S-bromowillardiine (acting on AMPA-kainate receptors) mimic some aspects of white matter cysts and transcortical necrosis observed in human perinatal brain damage associated with cerebral palsy. Exogenous and endogenous cannabinoids have received increasing attention as potential neuroprotective agents in a number of neurodegenerative disorders of the adult. One recent study showed neuroprotection by the cannabinoid agonist WIN-55212 in a newborn rat model of acute severe asphyxia. The present study was designed to assess the neuroprotective effects of the endogenous cannabinoid anandamide using a well-defined rodent...
Read More

Endocannabinoids: A Promising Impact for Traumatic Brain Injury

The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous nature in etiology, clinical presentation, and severity. Here, we review pre-clinical studies assessing the therapeutic potential of cannabinoids and manipulations of the...
Read More

Activation of Cannabinoid CB2 Receptor – Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury

The type 2 cannabinoid receptor (CB2R) was recently shown to mediate neuroprotection in ischemic injury. However, the role of CB2Rs in the central nervous system, especially neuronal and glial CB2Rs in the cortex, remains unclear. We, therefore, investigated anti-ischemic mechanisms of cortical CB2R activation in various ischemic models. In rat cortical neurons/glia mixed cultures, a CB2R agonist, trans-caryophyllene (TC), decreased neuronal injury and mitochondrial depolarization caused by oxygen-glucose deprivation/re-oxygenation (OGD/R); these effects were reversed by the selective CB2R antagonist, AM630, but not by a type 1 cannabinoid receptor antagonist, AM251. Although it lacked free radical scavenging and antioxidant enzyme induction activities, TC reduced OGD/R-evoked...
Read More

Future of Cannabis and Cannabinoids in Therapeutics

This study reviews human clinical experience to date with several synthetic cannabinoids, including nabilone, levonantradol, ajulemic acid (CT3), dexanabinol (HU-211), HU-308, and SR141716 (Rimonabant®). Additionally, the concept of “clinical endogenous cannabinoid deficiency” is explored as a possible factor in migraine, idiopathic bowel disease, fibromyalgia and other clinical pain states. The concept of analgesic synergy of cannabinoids and opioids is addressed. A cannabinoid-mediated improvement in night vision at the retinal level is discussed, as well as its potential application to treatment of retinitis pigmentosa and other conditions. Additionally noted is the role of cannabinoid treatment in neuroprotection and its application to closed head injury, cerebrovascular...
Read More

GPR55: A therapeutic target for Parkinson’s disease?

The GPR55 receptor is expressed abundantly in the brain, especially in the striatum, suggesting it might fulfill a role in motor function. Indeed, motor behavior is impaired in mice lacking GPR55, which also display dampened inflammatory responses. Abnormal-cannabidiol (Abn-CBD), a synthetic cannabidiol (CBD) isomer, is a GPR55 agonist that may serve as a therapeutic agent in the treatment of inflammatory diseases. In this study, we explored whether modulating GPR55 could also represent a therapeutic approach for the treatment of Parkinson's disease (PD). The distribution of GPR55 mRNA was first analyzed by in situ hybridization, localizing GPR55 transcripts to neurons in brain nuclei related to...
Read More

HU­211, a Novel Noncompetitive N­Methyl­D­Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat

Abstract Background and Purpose HU-211 is a nonpsychotropic cannabinoid analogue that has been shown to act as a functional N-methyl-d-aspartate receptor blocker. We investigated the neuroprotective efficacy of HU-211 in a model of reversible middle cerebral artery occlusion (MCAo) in rats. Methods Male Wistar rats were anesthetized with halothane and subjected to 90 minutes of temporary MCAo by retrograde insertion of an intraluminal nylon suture, coated with poly-l-lysine, through the external carotid artery into the internal carotid artery and MCA. The drug (HU-211 in cosolvent, 4 mg/kg IV) or vehicle was administered in a blinded fashion 70 minutes after onset of MCAo. Behavioral tests were evaluated during...
Read More
« Previous 1 2 3 4 Next »

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2024 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer

Open the following in new tabs if you:

If you are already a user: Client Login

If you are not, then register: Client Registration

Once Logged in, click below to refresh the page.